New Research Report Reveals Cell and Gene Therapy CDMO Market to reach US$ 18.6 billion Worldwide - By PMI

Cell and Gene Therapy CDMO Market, By Service Area (Cell Therapy, Plasmid DNA, Viral Vector, and Others), By Indication (Cancer, Cardiovascular Disease, Infectious Disease, Genetic Disorders, Neurological Disorders), By Phase (Phase 1, Phase 2, Phase 3, Phase 4), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032


Covina, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Cell and Gene Therapy CDMO Market is expected to reach US$ 18.6 billion by 2032; Rising Demand for CDMOs from Emerging Pharmaceutical Companies to Propel Industrial Progress

Cell and Gene Therapy plays an important role in today’s healthcare, to treat, and potentially cures diseases. Cell and Gene therapy CDMO are used for development of new modalities such as gene therapies, cell therapies, and innovative vaccines necessitates a significant investment in new manufacturing facilities for cell manipulation, viral vectors, nucleic acid and lipid-based formulations.

As CDMOs are able to flexibly alter their production lines to meet the rising demand of smaller and diverse projects, foster the growth of target market. Further, New partnerships with pharmaceutical and biotechnology companies have enabled CDMO players to fuel the rapid growth of capabilities and capacities by helping industries succeed in drug and vaccine production. Integration of clinical trial services is expected to become a new trend for CDMOs as they enter high-value, low-volume segments such as personalized medicine. Technological advancement in Cell and Gene Therapy has also driven the market's growth.

The report “Cell and Gene Therapy CDMO Market, By Service Area (Cell Therapy, Plasmid DNA, Viral Vector, and Others), By Indication (Cancer, Cardiovascular Disease, Infectious Disease, Genetic Disorders, Neurological Disorders), By Phase (Phase 1, Phase 2, Phase 3, Phase 4), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032”

Key Highlights:

  • In August 2022, Charles River Laboratories International Inc., announced that it had received regulatory approval in the form of GMP (Good Manufacturing Practice) certification for the commercial production of allogeneic cell therapy drug products for distribution in Europe. The company has been awarded a commercial GMP license for a successful EMA inspection of its Memphis CDMO facility.
  • In May 2020, WuXi Advanced launched its world-class closed-process CAR-T cell therapy platform. A newly launched platform will enable researchers and biotech companies to accelerate the manufacturing, development, and release of cell and gene therapies for patients.

Request Free Sample Copy of the Report: 

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/5065

Analyst View:

Cell and gene therapy has become a complex field that requires a high level of expertise and robust manufacturing facilities. As Cell and Gene Therapy requires costly production and various manufacturing processes, outsourcing services to CDMOs is increasing. CDMOs aid in the formation of long-term partnerships that benefit the success of current products as well as the manufacturing of future products of key player’s pipeline along with business expansion. However, rising demand for outsourcing cell and gene therapy development and production due to a lack of manufacturing facilities and high costs is expected to boost the target market. Further, emerging pharmaceutical companies, which are also involved in research and development of cell and gene therapy, and have low funding in turn will opt for CDMO. As a result, market competition is intensifying, and both big international corporations and start-ups are vying to establish positions in the market.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on  Cell and Gene Therapy CDMO Market, By Service Area (Cell Therapy, Plasmid DNA, Viral Vector, and Others), By Indication (Cancer, Cardiovascular Disease, Infectious Disease, Genetic Disorders, Neurological Disorders), By Phase (Phase 1, Phase 2, Phase 3, Phase 4), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032”

Key Market Insights from the report:

Cell and Gene Therapy CDMO Market accounted for US$ 3.2 billion in 2022 and is estimated to be US$ 18.6 billion by 2032 and is anticipated to register a CAGR of 18.1%. The Cell and Gene Therapy CDMO Market is segmented based on Service Area, Indication, Phase and Region.

  • Based on Service Area, Cell and Gene Therapy CDMO Market is segmented into Cell Therapy, Plasmid DNA, Viral Vector, and others.
  • Based on Indication, Cell and Gene Therapy CDMO Market is segmented into Cancer, Cardiovascular Disease, Infectious Disease, Genetic Disorders, Neurological Disorders.
  • Based on Phase, Cell and Gene Therapy CDMO Market is segmented into Phase 1, Phase 2, Phase 3, Phase 4.
  • By Region, the Cell and Gene Therapy CDMO Market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Competitive Landscape & their strategies of Cell and Gene Therapy CDMO Market:

The prominent players operating in the Cell and Gene Therapy CDMO Market includes, Catalent Inc., Lonza Group, Recipharm AB, Wuxi Advanced Therapies, Pfizer CentreOne, Charles River Laboratories International Inc., Patheon Inc., Almac Group, FUJIFILM Diosynth Biotechnologies, PCI Pharma Services, and others.

Scope of the Report: 

  1. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restrains
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  2. Cell and Gene Therapy CDMO Market, By Service Area
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Cell Therapy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Plasmid DNA
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Viral Vector
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  3. Cell and Gene Therapy CDMO Market, By Indication, 2022 – 2032, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Cancer
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Cardiovascular Disease
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Infectious Disease
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Genetic Disorders
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Neurological Disorders
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  4. Cell and Gene Therapy CDMO Market, By Phase, 2022 – 2032, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Phase 1
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Phase 2
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Phase 3
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Phase 4
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032

For Customization: https://www.prophecymarketinsights.com/market_insight/Insight/request-customization/5065

Key Questions Answered by Cell and Gene Therapy CDMO Market Research Report: 

  1. What is the current market size of the Cell and Gene Therapy CDMO industry, and what is the forecasted growth rate for the next few years?
  2. What are the key drivers, restraints, and opportunities in the Cell and Gene Therapy CDMO market, and how are they likely to impact the market?
  3. Who are the major players in the Cell and Gene Therapy CDMO market, and what are their key strategies and competitive advantages?
  4. What are the different types of services offered by Cell and Gene Therapy CDMOs, and what is the market share of each type?
  5. What are the key applications of Cell and Gene Therapy CDMOs, and which applications are likely to experience the fastest growth in the coming years?
  6. What are the major technological advancements and innovations in the Cell and Gene Therapy CDMO industry, and how are they likely to shape the market in the future?
  7. What are the major challenges facing the Cell and Gene Therapy CDMO market, such as regulatory issues or supply chain constraints, and how can they be addressed?
  8. Which regions are likely to experience the fastest growth in the Cell and Gene Therapy CDMO market, and what are the key factors driving this growth?

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Browse Related Reports: 

1. Cell and Gene Therapy Market, By Products (Cell Therapy, and Gene Therapy), By Distribution Channel Type (Oncology, Dermatology, Musculoskeletal, and Others), By End-Users (Hospitals, Wound Care Centers, Cancer Care Centers, Ambulatory Surgical Centers, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

2. Global Pharmaceutical and Biotechnology Market, By Product Type(Vaccines (Recombinant Vaccines, Conventional Vaccines, Recombinant Enzymes, Cell and Gene Therapies and Other Product Types) and Synthetic Immuno-modulators (Cytokines, Interferones, Interleukins and Tumor Necrosis Factor)),By Therapeutic Application (Oncology, Inflammatory and Infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, Disease Prevention, Cardiovascular Diseases, Neurological Diseases and Other Diseases) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)Trends, Analysis and Forecast till 2029

3. Generic Sterile Injectables Market, By Drug Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines, Immunoglobulin, Blood Factors, Antibiotics, and Others), By Therapeutic Application (Cancer, Diabetes, Cardiovascular Disease, Central Nervous System, Musculoskeletal System, and Others), By Distribution Channel (Hospitals, Drug Stores, and Retail Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2029

Follow us 

Linkedin | Twitter | Facebook

 

Coordonnées